scholarly journals Cancer diagnosis is associated with equivalent ovarian reserve, response to ovarian stimulation and fertility preservation outcome when compared to elective oocyte cryopreservation

2016 ◽  
Vol 106 (3) ◽  
pp. e126-e127 ◽  
Author(s):  
M. Quinn ◽  
H. Cakmak ◽  
J. Letourneau ◽  
M. Cedars ◽  
M. Rosen
Author(s):  
Halime Goktepe ◽  
Esengul Turkyilmaz ◽  
Gulsen Dogan Durdag ◽  
Murat Sonmezer ◽  
Cem Atabekoglu ◽  
...  

<p><strong>OBJECTIVE:</strong> To analyze demographic and clinical data of patients who resorted to oocyte freezing between January 2014 and December 2018. </p><p><strong>STUDY DESIGN:</strong> Patients who applied to the Reproductive Endocrinology and Infertility Unit of Ankara University School of Medicine between January 2014 and December 2018 with the request of oocyte freezing were included in this study. The files and computer records of the patients were analyzed retrospectively and sociodemographic, clinical and laboratory data were evaluated. </p><p><strong>RESULTS:</strong> A total of 46 cycles were recorded in 40 patients over a 5-year period. The main indications were low ovarian reserve and/or advanced age (68.3%) and malignancy diagnosis (31.7%). There was a significant difference between elective fertility preservation and oncofertility preservation (Onco-FP) groups in terms of the age (38.4±4.7 vs 28.4±6.1; p=0.001). There was a significant difference between two groups in favor of oncofertility group in terms of anti-Mullerian hormone level, basal follicle-stimulating hormone level, antral follicle count, trigger day estradiol (E2) level, number of obtained oocytes, MII oocytes, and frozen oocytes</p><p><strong>CONCLUSION:</strong> According to our study, the most prominent oocyte cryopreservation indication was advanced age and/or low ovarian reserve. The number of oocytes collected from patients in the Onco-FP group and thus the number of frozen oocytes was significantly higher than in the elective fertility preservation group, due to younger ages and better ovarian reserve in the Onco-FP group. Abdominal administration of the technique is particularly important for virgin patients in our country. Oocyte freezing is a fertility protection method available in a wide range of indications for reproductive-aged women.</p>


2020 ◽  
Vol 47 (4) ◽  
pp. 306-311
Author(s):  
Se Jeong Kim ◽  
Tae Hyung Kim ◽  
Jae Kyun Park ◽  
Jin Hee Eum ◽  
Woo Sik Lee ◽  
...  

Objective: The aim of this study was to determine whether co-administration of a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) for final oocyte maturation improved mature oocyte cryopreservation outcomes in young women with decreased ovarian reserve (DOR) compared with hCG alone.Methods: Between January 2016 and August 2019, controlled ovarian stimulation (COS) cycles in women (aged ≤35 years, anti-Müllerian hormone [AMH] <1.2 ng/mL) who underwent elective oocyte cryopreservation for fertility preservation were retrospectively analyzed.Results: A total of 76 COS cycles were triggered with a GnRH agonist and hCG (the dual group) or hCG alone (the hCG group). The mean age and serum AMH levels were comparable between the two groups. The duration of stimulation, total dose of follicle-stimulating hormone used, and total number of oocytes retrieved were similar. However, the number of mature oocytes retrieved and the oocyte maturation rate were significantly higher in the dual group than in the hCG group (p=0.010, p<0.001). After controlling for confounders, the dual-trigger method remained a significant factor related to the number of mature oocytes retrieved (p=0.016).Conclusion: We showed improved mature oocyte collection and maturation rate with the dual triggering of oocyte maturation in young women with DOR. A dual trigger appears to be more beneficial than hCG alone in terms of mature oocyte cryopreservation for young women with DOR.


Sign in / Sign up

Export Citation Format

Share Document